StreetAlpha.app
Home › Stocks › RNAC

Cartesian Therapeutics, Inc. (RNAC)

$6.12
▲ +0.66%
LAST CLOSE · NOV 17

Cartesian Therapeutics develops mRNA-based cell therapies for autoimmune diseases, starting with its lead candidate for myasthenia gravis. It last closed at $6.12 on Nov 17, up 0.66% on the day.

AI Auto Pilots
Is RNAC in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$1.0M
−6.0% vs a year ago
Net income
−$127.5M
−12435.2% margin
EPS (diluted)
−$4.78
Free cash flow
−$89.9M
−8770.0% margin
Valuation
Market cap
$186.7M
30.5M shares
P/E
–
No P/E while losing money
Price to sales
182.1
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$123.0M
At Sep 30
Debt
$50.2M
At Sep 30
Shareholder equity
−$130.5M
Shares outstanding
30.5M
At Oct 31
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $85.1M$85.1MFY2021FY2022: $110.8M$110.8MFY2022FY2023: $26.0M$26.0MFY2023FY2024: $38.9M$38.9MFY2024FY2025: $2.8M$2.8MFY2025

From RNAC's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Last report
Nov 5
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated RNAC in the past 90 days, not enough for a consensus
Average 12-month target
$40.00
▲ 553.6% upside

Based on 1 analyst who set a price target on RNAC in the past 90 days. The average target is $40.00, with a high of $40.00 and a low of $40.00, compared with the last close of $6.12.

Low $40.00Avg $40.00High $40.00
Blue marker: last close $6.12
Highest target$40.00
Average target$40.00
Lowest target$40.00
Latest rating changes
NeedhamReiterated
Sep 29Buy$40
BTIGReiterated
Jun 9Buy$44
NeedhamMaintained
May 26Buy$40
DateFirmActionRatingPrice target
Sep 29NeedhamReiteratedBuy$40
Jun 9BTIGReiteratedBuy$44
May 26NeedhamMaintainedBuy$40
Loading…

Technical Analysis

RNAC · as of the Nov 17 close · updated after every close
Downtrend

The stock is 7% below its 20 day and 15% below its 50 day average. It is 24% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 39). The nearest support is the Pivot at $6.07, and the nearest resistance the Pivot R1 at $6.22.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNormal
VolatilityNormal, 7.4%/day
Key levels
$11.0052 week high+79.7%
$8.03100 day average+31.2%
$7.61200 day average+24.3%
$7.0250 day average+14.7%
$6.71Swing high (Oct 21)+9.6%
$6.5620 day average+7.2%
$6.22Pivot R1+1.6%
$6.12Last close
$6.07Pivot−0.8%
$6.07Swing low (Oct 26)−0.8%
$5.98Pivot S1−2.3%
$5.6052 week low−8.5%
Indicators
RSI (14)39.40Weak, oversold below 30Neutral
MACD-0.17Below its signal lineBearish
Stochastic7.7Near the bottom of its rangeOversold
ADX (14)14.3No clear trend
Williams %R-90.4Oversold below −80, overbought above −20Oversold
CCI (20)-127.5Oversold below −100, overbought above 100Oversold
Rate of change−4.5%Change over 10 sessionsBearish
ATR (14)$0.45Typical daily range, 7.4% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for RNAC

What happened before

See how RNAC did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow RNAC usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How RNAC has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2016.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in RNAC in the last 90 days.

Loading…

See today’s whale options flow across the market →

RNAC Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ●44 buying vs 42 selling
  • ●Held by funds +0.2 pts
  • ▲Funds holding +5
  • ▲Superinvestors: 3 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding10095+5.3%
In funds' top 1000–
Held by funds28.7%28.5%+0.2 pts
New / increased11 / 3324 / 44−35.3%
Reduced / sold out35 / 712 / 12+75.0%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See RNAC institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether RNAC is in one of them and how their past RNAC trades turned out.

RNAC in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered RNAC in an article yet. Here's the latest on the wider market.

About Cartesian Therapeutics

Cartesian Therapeutics is a biotechnology company based in Frederick, Maryland, that is developing cell therapies for autoimmune diseases. Its approach uses mRNA to deliver a chimeric antigen receptor into a patient's own immune cells, which are then returned to the patient for outpatient treatment. Its lead product candidate, Descartes-08, is in clinical development for myasthenia gravis and certain myositis conditions. The company's target customers are patients with these conditions, and its products are not yet approved for sale.

Headquarters
Frederick, MD
Founded
2008